Cargando…
Therapeutic versus prophylactic heparin for thromboprophylaxis in patients with COVID-19: weighing the costs and benefits. A rapid meta-analysis of randomized controlled trials
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Termedia Publishing House
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487802/ https://www.ncbi.nlm.nih.gov/pubmed/36158066 http://dx.doi.org/10.5114/amsad/150507 |
| _version_ | 1784792521016082432 |
|---|---|
| author | Dimosiari, Athina Patoulias, Dimitrios |
| author_facet | Dimosiari, Athina Patoulias, Dimitrios |
| author_sort | Dimosiari, Athina |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9487802 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Termedia Publishing House |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94878022022-09-22 Therapeutic versus prophylactic heparin for thromboprophylaxis in patients with COVID-19: weighing the costs and benefits. A rapid meta-analysis of randomized controlled trials Dimosiari, Athina Patoulias, Dimitrios Arch Med Sci Atheroscler Dis Letter to the Editor Termedia Publishing House 2022-08-08 /pmc/articles/PMC9487802/ /pubmed/36158066 http://dx.doi.org/10.5114/amsad/150507 Text en Copyright: © 2022 Termedia & Banach https://creativecommons.org/licenses/by-nc-sa/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license. |
| spellingShingle | Letter to the Editor Dimosiari, Athina Patoulias, Dimitrios Therapeutic versus prophylactic heparin for thromboprophylaxis in patients with COVID-19: weighing the costs and benefits. A rapid meta-analysis of randomized controlled trials |
| title | Therapeutic versus prophylactic heparin for thromboprophylaxis in patients with COVID-19: weighing the costs and benefits. A rapid meta-analysis of randomized controlled trials |
| title_full | Therapeutic versus prophylactic heparin for thromboprophylaxis in patients with COVID-19: weighing the costs and benefits. A rapid meta-analysis of randomized controlled trials |
| title_fullStr | Therapeutic versus prophylactic heparin for thromboprophylaxis in patients with COVID-19: weighing the costs and benefits. A rapid meta-analysis of randomized controlled trials |
| title_full_unstemmed | Therapeutic versus prophylactic heparin for thromboprophylaxis in patients with COVID-19: weighing the costs and benefits. A rapid meta-analysis of randomized controlled trials |
| title_short | Therapeutic versus prophylactic heparin for thromboprophylaxis in patients with COVID-19: weighing the costs and benefits. A rapid meta-analysis of randomized controlled trials |
| title_sort | therapeutic versus prophylactic heparin for thromboprophylaxis in patients with covid-19: weighing the costs and benefits. a rapid meta-analysis of randomized controlled trials |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487802/ https://www.ncbi.nlm.nih.gov/pubmed/36158066 http://dx.doi.org/10.5114/amsad/150507 |
| work_keys_str_mv | AT dimosiariathina therapeuticversusprophylacticheparinforthromboprophylaxisinpatientswithcovid19weighingthecostsandbenefitsarapidmetaanalysisofrandomizedcontrolledtrials AT patouliasdimitrios therapeuticversusprophylacticheparinforthromboprophylaxisinpatientswithcovid19weighingthecostsandbenefitsarapidmetaanalysisofrandomizedcontrolledtrials |